Meeting
2022 ASCO Annual Meeting
Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in patients with ER+/HER2-breast cancer with 1-3 positive nodes and Oncotype DX recurrence score 20 to 25: A National Cancer Database analysis.
Authors
Lifen Cao
University Hospitals at Cleveland Medical Center, Cleveland, OH
Lifen Cao , Christopher W. Towe , Xun Luo , Nickolas Stabellini , Amanda L. Amin , Alberto J. Montero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 540)
DOI
10.1200/JCO.2022.40.16_suppl.540
Abstract #
540
Poster Bd #
312
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
First Author: Lifen Cao
Poster
2021 ASCO Annual Meeting
Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.
First Author: Vladislav Berdunov
Poster
2013 Breast Cancer Symposium
Can Oncotype DX recurrence score (RS) be used in Luminal A and Luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective unicentric study in Spanish population.
First Author: Laura G. Estevez
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinical significance of time interval between surgery and adjuvant chemotherapy in patients with gastric cancer after gastrectomy: A population-based cohort study using a nationwide claims database.
First Author: Chi Hoon Maeng